Improving Vaccines to Advance Health Equity
Elarex’s mission is to create the next generation vaccine platform to reduce dependence on the cold chain and advance health equity.
Revolutionizing Vaccine Distribution:
A Leap Towards Global Health Equity
In the heart of the global health landscape, a silent crisis is unfolding. Each year, millions of life-saving vaccines fail to reach the individuals who need them the most. The culprit is a lack of temperature stability in vaccine formulations, a challenge that disproportionately affects low and middle-income countries.
Today, vaccines must navigate a complex journey from manufacturers to patients. This “cold chain” requires constant refrigeration, a resource that is often scarce in remote or under-resourced regions. Any disruption can render vaccines ineffective, wasting precious resources and leaving communities vulnerable to preventable diseases.
Elarex’s patented formulation and process technology is set to transform this landscape. Unlike current solutions, our technology offers superior temperature stability, ensuring that vaccines retain their potency even in the most challenging conditions.
Robust, Cost-Effective and FDA Compliant Technology
Our technology is not only robust but also cost-effective and simple to implement. It integrates seamlessly into the vaccine production process, keeping costs low and making it an attractive solution for vaccine manufacturers worldwide. The components of our formulation are also safe and found on the FDA GRAS list.
Preliminary studies have shown promising results. Our technology has demonstrated superior virus stabilization compared to traditional drying methods. This breakthrough has the potential to revolutionize vaccine distribution, in and outside of the cold chain.
Innovating for a Healthier World through Enhanced Vaccine Stability
By improving the temperature stability of vaccines, we can strengthen the resilience of the global vaccine supply chain. More vaccines will reach their destinations potent and effective, leading to higher vaccination rates, fewer disease outbreaks, and ultimately, healthier communities.
At Elarex, we believe in the power of innovation to advance health equity. Our technology is more than just a scientific breakthrough; it’s a leap toward a healthier, more equitable world. Join us as we embark on this exciting journey towards global impact.
Impact Areas
Elarex is focused on some of the most important and deadly viruses.
Most of these have no vaccine or a vaccine that is difficult or costly to distribute due to the cold chain requirements. A new vaccine that can be distributed outside of a cold chain, would make it easier to transport and store in low- and middle-income countries, which are some of the most affected regions by emerging viral diseases. This could be a game-changer for small communities that are otherwise unreachable by vaccine drives.
Reaching these small communities is the difference between controlling a disease within the local area and a wide-scale outbreak that can affect tens of millions of people. By leaving no one unprotected, a thermostable vaccine alleviates the burden on these delicate health care systems. It is a breakthrough that allows the residents to thrive individually and collectively. Above all, it represents a significant step towards ending the global health threat posed by Ebola, Dengue, Rotavirus, and Lassa fever.
Our advantage is built on our breakthrough stabilization technology and driven by our disciplined inquisitive approach.
Copyright © – © Elarex Inc. All rights reserved. | Website Developed & Managed by GlobeSign